Cleveland Clinic Nephrology Update 2026

Cleveland Clinic Nephrology Update 2026 is designed to provide a comprehensive review of the most up-to-date scientific data and analyze its implications for clinical practice. The program focuses on recent and emerging topics that directly impact day-to-day patient care. Led by expert faculty, the course addresses diagnostic and management strategies for patients with various kidney diseases, covering areas such as hypertension, cardio-kidney-metabolic syndrome, cystic kidney diseases, glomerular diseases, and vasculitis.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Describe advances in the management of ADPKD and other cystic kidney diseases and review their impact on clinical practice.

• Provide an update on the pathogenesis and treatment of various glomerular diseases including IgA nephropathy, anti-GBM disease, ANCA-associated glomerulonephritis, lupus nephritis, thrombotic microangiopathy, and APOL1 nephropathy.

• Summarize the safety and efficacy of newer therapies for hypertension, including renal denervation, aldosterone synthase inhibitors, endothelin receptor agonists, and hepatic angiotensinogen silencing RNA, and describe their use in clinical practice, especially for resistant hypertension.

• Evaluate the latest evidence-based treatment strategies for hepato-renal and cardio-renal syndromes.

• Highlight updated approaches to managing kidney-related complications in cancer patients, including the nephrotoxic effects of immune checkpoint inhibitors and targeted cancer therapeutics.

Target Audience

• This activity is designed for nephrologists, cardiologists, intensive care specialists, internists, nurses, nurse practitioners, physician assistants, and other practicing health care professionals who desire an update on recent advancements in chronic kidney disease management and treatment strategies.
• Best for Nephrologists, Cardiologists, Critical Care Physicians, Oncologists, and Palliative Medicine Specialists.

Topics

• 1. Mineral Bone Disease in CKD

• 2. Metabolic Acidosis in CKD

• 3. Saving Kidneys, Hearts, and Lives_ Understanding Cardiovascular-Kidney-Metabolic Syndrome

• 4. Hyperkalemia and RAAS Inhibitors_ Saving Kidneys, Hearts, and Lives

• 5. GLP-RA and the Kidneys_ a Nephrologist Perspective

• 6. Cardiovascular Risk Reduction and Hyperlipidemia Management in CKD

• 7. ADPKD Update

• 8. Non-ADPKD Cystic Kidney Disease Cases

• 9. Case Discussions in ADPKD

• 10. Journal Club_1

• 11. Journal Club_2

• 11. APOL1 Nephropathy

• 12. Precision Medicine in Glomerular Diseases _ Neptune Match

• 13. Update on ANCA Disease_ Reducing the Steroid Burden

• 14. IgA Nephropathy_ Update on Pathogenesis and Treatment

• 15. Complement Across Glomerular Diseases

• 16. Clinicopathologic Case Discussions

• 17. Introduction_ Kasperzak Talk

• 18. Kasperzak Talk Anti-GBM Disease_ A State of the Art Update

• 19. Future Directions in Lupus Nephritis Management

• 20. Select Cases from the CCF GN Clinic

• 21. Thrombotic Microangiopathy_ a-HUS and Beyond

• 22. Clinicopathologic Case Discussions

• 23. Hypertension Guidelines Update

• 24. Update on Hyperaldosteronism

• 25. Practical Approach to Resistant Hypertension

• 26. Medical Therapy in Hypertension_ An Evolving Landscape

• 27. Update on Renal Denervation

• 28. Innovations in BP Measurement

• 29. Updates in Hepato-Renal Syndrome

• 30. Cardio-Renal Syndrome

• 31. AKI in Cancer

• 32. AKI in the ICU

• 33. Palliative Medicine Workshop_1

• 33. Palliative Medicine Workshop_2

• Session I_ Cardiovascular Kidney Metabolic Syndrome, Part I

• Session II_ Cardiovascular Kidney Metabolic Syndrome, Part II

• Session III_ Cystic Kidney Diseases

• Session IV_ Journal Club

• Session V_ Glomerular Disease Update, Part I

• Session VI_ Glomerular Disease Update, Part II

• Session VII_ Glomerular Disease Update, Part III

• Session VIII_ Glomerular Disease Update, Part IV

• Session IX_ Hypertension Updates, Part I

• Session X_ Hypertension Updates, Part II

• Session XI_ AKI in Special Populations, Part I

• Session XII_ AKI in Special Populations, Part II